Devana Solutions has announced the completed integration of its Ignite platform with the Clinical Research IO (CRIO) clinical trial management platform. The measure is intended to help users increase efficiency, decrease trial cycle times, and speed the availability of new therapies to patients.
The Ignite platform is intended to automate trial workflows, capture important timing metrics, and provide robust reporting during study startup, screening and enrollment. The purpose of the CRIO integration is to further simplify trial processes and introduce more efficiency.
Devana Solutions director of strategic partnerships Emily Wike told Outsourcing-Pharma that pairing the Ignite and CRIO platforms helps trial teams realize a number of benefits around efficiency and effectiveness.
“The combined technologies allow for a more streamlined approach to collecting data by eliminating the need to input critical study information into separate systems,” she said. “Essentially, all data captured in either system is automatically transferred into and seamlessly displayed in the other platform.”
CRIO co-founder Raymond Nomizu said his company is known for being an organization that “seamlessly addresses” any challenges that sites and sponsors encounter in their trials.
“Our collaboration with another industry trail blazer, Devana, is a partnership that will further increase clinical trial efficiency,” Nomizu said. “A data-driven approach enhances every site’s ability to make critical decisions and taking advantage of our technology allows sites to gather and analyze more data than ever before.”
Wike said Devana plans to announce additional partnerships with Bio-Optronics and other organizations in the future, as well as reveal additional features to other platforms.
“One such development is our new Site Capabilities feature that will soon be available to all of our Propel users,” she said. “This new feature will allow users to centrally manage their sites’ capabilities and run queries to help match the best sites with the right protocols.”